EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Low-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial

Takeshi Nagao iD, Ken Takahashi, Sho Takahashi, Ryo Yokomizo iD, Osamu Samura, Aikou Okamoto

PLOS ONE · 12.03.2025 · 20 (3) · e0319795

DOI: 10.1371/journal.pone.0319795 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, online erschienen am 12.03.2025. Verfasst von Takeshi Nagao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Anemia, Iron-Deficiency, Ferric Compounds, Hemoglobins, Iron. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferric carboxymaltose (FCM) is widely used to correct anemia and replenish iron stores rapidly, particularly in Western populations. However, lower doses of FCM are typically used in East Asia, with limited research on their effectiveness, especially in postpartum women. This randomized controlled trial aimed to assess the efficacy of low-dose FCM compared with oral ferrous sulfate in increasing postpartum hemoglobin (Hb) levels and replenishing iron stores in East Asian women. Sixty postpartum women with Hb levels < 10 g/dL and serum ferritin ≤ 30 ng/mL were randomized to receive either intravenous FCM (500 mg at baseline and 2 weeks) or oral ferrous sulfate (210 mg daily for 4 weeks). The primary outcome was the increase in Hb levels at 2 weeks post-enrollment. Secondary outcomes included serum ferritin, transferrin saturation, the Edinburgh Postnatal Depression Scale (EPDS) score, and adverse events at 4 weeks. The FCM group demonstrated a significantly greater increase in Hb levels at 2 weeks (mean difference 0.42 g/dL; 95% CI: 0.12–0.72; P = 0.006), with markedly higher ferritin (adjusted mean difference 356.0 ng/mL; 95% CI: 321.0–403.0; P < 0.001) and transferrin saturation (adjusted mean difference 10.76%; 95% CI: 4.20–17.31; P = 0.002) at 4 weeks. Although there was no significant difference in final Hb levels at 4 weeks (mean difference 0.36 g/dL; 95% CI: -0.01–0.72; P = 0.055), the FCM group had a lower median EPDS score (median difference -3.0; 95% CI: -5.0 to -1.0; P = 0.002) and fewer gastrointestinal side effects, including constipation and nausea. Hypophosphatemia occurred asymptomatically in three patients in the FCM group. These findings suggest that low-dose FCM infusion is highly effective in increasing Hb levels at 2 weeks post-enrollment, with fewer gastrointestinal side effects and higher ferritin levels observed at 4 weeks post-enrollment compared with oral ferrous sulfate. This study was registered at the UMIN Clinical Trials Registry, which meets the requirements of the ICMJE, on December 1, 2021 (ID: UMIN000046049).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Iron-DeficiencyFerric CompoundsHemoglobinsIronMaltosePostpartum PeriodAdultFemaleHumansYoung AdultAdministration, OralEast Asian PeopleFerritinsFerrous Compounds

Substanzen

ferric carboxymaltoseFerric CompoundsFerritinsFerrous Compoundsferrous sulfateHemoglobinsIronMaltose

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Center for Research Promotion, The Jikei University School of Medicine, Tokyo, Japan.

ORCID-Profile: Takeshi Nagao, Ryo Yokomizo

Zitieren

APA

Nagao, T., Takahashi, K., Takahashi, S., Yokomizo, R., Samura, O., & Okamoto, A. (2025). Low-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial. PLOS ONE, 20(3), e0319795. https://doi.org/10.1371/journal.pone.0319795

Vancouver

Nagao T, Takahashi K, Takahashi S, Yokomizo R, Samura O, Okamoto A. Low-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial. PLOS ONE. 2025;20(3):e0319795. doi:10.1371/journal.pone.0319795

BibTeX
@article{Nagao2025,
  author = {Nagao, Takeshi and Takahashi, Ken and Takahashi, Sho and Yokomizo, Ryo and Samura, Osamu and Okamoto, Aikou},
  title = {Low-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {e0319795},
  doi = {10.1371/journal.pone.0319795}
}
Kostenlos starten →